Maziar Behbahani1,2, Geir Olve Skeie3, Geir Egil Eide4,5, Annbjørg Hausken1, Morten Lund-Johansen1,6, Bente Sandvei Skeie1. 1. Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway. 2. Department of Neurosurgery, Stavanger University Hospital, Norway. 3. Department of Neurology, Haukeland University Hospital, Bergen, Norway. 4. Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway. 5. Department of Global Public Health and Primary Care, University of Bergen, Norway. 6. Department of Clinical Medicine, University of Bergen, Norway.
Abstract
BACKGROUND: The number of incidental meningiomas has increased because of the increased availability of neuroimaging. Lack of prospective data on the natural history makes the optimal management unclear. We conducted a 5-year prospective study of incidental meningiomas to identify risk factors for tumor growth. METHODS: Sixty-four of 70 consecutive patients with incidental meningioma were included. Clinical and radiological status was obtained at 0, 0.5, 1, 1.5, 2, 3, 4, and 5 years. GammaPlan and mixed linear regression modeling were utilized for volumetric analysis with primary endpoint tumor growth. RESULTS: None of the patients developed tumor-related symptoms during the study period, although 48 (75%) tumors increased (>15%), 13 (20.3%) remained unchanged, and 3 (4.7%) decreased (>15%) in volume. Mean time to growth was 2.2 years (range, 0.5-5.0 years).The growth pattern was quasi-exponential in 26%, linear in 17%, sigmoidal in 35%, parabolic in 17%, and continuous reduction in 5%. There was significant correlation among growth rate, larger baseline tumor volume (P < .001), and age in years (<55 y: 0.10 cm3/y, 55-75 y: 0.24 cm3/y, and >75 y: 0.85 cm3/y). CONCLUSION: The majority of meningiomas will eventually grow. However, more than 60% display a self-limiting growth pattern. Our study provides level-2 evidence that asymptomatic tumors can be safely managed utilizing serial imaging until persistent radiological and/or symptomatic growth.
BACKGROUND: The number of incidental meningiomas has increased because of the increased availability of neuroimaging. Lack of prospective data on the natural history makes the optimal management unclear. We conducted a 5-year prospective study of incidental meningiomas to identify risk factors for tumor growth. METHODS: Sixty-four of 70 consecutive patients with incidental meningioma were included. Clinical and radiological status was obtained at 0, 0.5, 1, 1.5, 2, 3, 4, and 5 years. GammaPlan and mixed linear regression modeling were utilized for volumetric analysis with primary endpoint tumor growth. RESULTS: None of the patients developed tumor-related symptoms during the study period, although 48 (75%) tumors increased (>15%), 13 (20.3%) remained unchanged, and 3 (4.7%) decreased (>15%) in volume. Mean time to growth was 2.2 years (range, 0.5-5.0 years).The growth pattern was quasi-exponential in 26%, linear in 17%, sigmoidal in 35%, parabolic in 17%, and continuous reduction in 5%. There was significant correlation among growth rate, larger baseline tumor volume (P < .001), and age in years (<55 y: 0.10 cm3/y, 55-75 y: 0.24 cm3/y, and >75 y: 0.85 cm3/y). CONCLUSION: The majority of meningiomas will eventually grow. However, more than 60% display a self-limiting growth pattern. Our study provides level-2 evidence that asymptomatic tumors can be safely managed utilizing serial imaging until persistent radiological and/or symptomatic growth.
Authors: Daniel M Fountain; Wai Cheong Soon; Tomasz Matys; Mathew R Guilfoyle; Ramez Kirollos; Thomas Santarius Journal: Acta Neurochir (Wien) Date: 2017-01-18 Impact factor: 2.216
Authors: Roland Goldbrunner; Giuseppe Minniti; Matthias Preusser; Michael D Jenkinson; Kita Sallabanda; Emmanuel Houdart; Andreas von Deimling; Pantelis Stavrinou; Florence Lefranc; Morten Lund-Johansen; Elizabeth Cohen-Jonathan Moyal; Dieta Brandsma; Roger Henriksson; Riccardo Soffietti; Michael Weller Journal: Lancet Oncol Date: 2016-08-30 Impact factor: 41.316
Authors: Pedro David Delgado-López; Antonio Montalvo-Afonso; Javier Martín-Alonso; Vicente Martín-Velasco; José Manuel Castilla-Díez; Ana María Galacho-Harriero; Sara Ortega-Cubero; Antonio Sánchez-Rodríguez; Antonio Rodríguez-Salazar Journal: Acta Neurochir (Wien) Date: 2021-03-22 Impact factor: 2.216
Authors: Maximilian I Ruge; Juman Tutunji; Daniel Rueß; Eren Celik; Christian Baues; Harald Treuer; Martin Kocher; Stefan Grau Journal: Radiat Oncol Date: 2021-01-28 Impact factor: 3.481
Authors: Abdurrahman I Islim; Georgios Mantziaris; Stylianos Pikis; Ching-Jen Chen; Adomas Bunevicius; Selçuk Peker; Yavuz Samanci; Ahmed M Nabeel; Wael A Reda; Sameh R Tawadros; Amr M N El-Shehaby; Khaled Abdelkarim; Reem M Emad; Violaine Delabar; David Mathieu; Cheng-Chia Lee; Huai-Che Yang; Roman Liscak; Jaromir May; Roberto Martinez Alvarez; Nuria Martinez Moreno; Manjul Tripathi; Douglas Kondziolka; Herwin Speckter; Camilo Albert; Greg N Bowden; Ronald J Benveniste; Lawrence Dade Lunsford; Jason P Sheehan; Michael D Jenkinson Journal: Cancers (Basel) Date: 2022-03-03 Impact factor: 6.639
Authors: Conor S Gillespie; Abdurrahman I Islim; Basel A Taweel; Christopher P Millward; Siddhant Kumar; Nitika Rathi; Shaveta Mehta; Brian J Haylock; Nicola Thorp; Catherine E Gilkes; David D A Lawson; Samantha J Mills; Emmanuel Chavredakis; Jibril Osman Farah; Andrew R Brodbelt; Michael D Jenkinson Journal: J Neurooncol Date: 2021-04-22 Impact factor: 4.130
Authors: Jason Sheehan; Stylianos Pikis; Abdurrahman I Islim; Ching-Jen Chen; Adomas Bunevicius; Selcuk Peker; Yavuz Samanci; Ahmed M Nabeel; Wael A Reda; Sameh R Tawadros; Amr M N El-Shehaby; Khaled Abdelkarim; Reem M Emad; Violaine Delabar; David Mathieu; Cheng-Chia Lee; Huai-Che Yang; Roman Liscak; Jaromir Hanuska; Roberto Martinez Alvarez; Dev Patel; Douglas Kondziolka; Nuria Martinez Moreno; Manjul Tripathi; Herwin Speckter; Camilo Albert; Greg N Bowden; Ronald J Benveniste; Lawrence Dade Lunsford; Michael D Jenkinson Journal: Neuro Oncol Date: 2022-01-05 Impact factor: 13.029
Authors: Roland Goldbrunner; Pantelis Stavrinou; Michael D Jenkinson; Felix Sahm; Christian Mawrin; Damien C Weber; Matthias Preusser; Giuseppe Minniti; Morten Lund-Johansen; Florence Lefranc; Emanuel Houdart; Kita Sallabanda; Emilie Le Rhun; David Nieuwenhuizen; Ghazaleh Tabatabai; Riccardo Soffietti; Michael Weller Journal: Neuro Oncol Date: 2021-11-02 Impact factor: 13.029
Authors: Sung Kwon Kim; Hong In Yoon; Wan Soo Yoon; Chul Kee Park; Youn Soo Lee; Ho Shin Gwak; Jin Mo Cho; Jangsup Moon; Kyung Hwan Kim; Se Hoon Kim; Young Il Kim; Young Zoon Kim; Ho Sung Kim; Yun Sik Dho; Jae Sung Park; Ji Eun Park; Youngbeom Seo; Kyoung Su Sung; Jin Ho Song; Chan Woo Wee; Se Hoon Lee; Do Hoon Lim; Jung Ho Im; Jong Hee Chang; Myung Hoon Han; Je Beom Hong; Kihwan Hwang Journal: Brain Tumor Res Treat Date: 2020-04
Authors: Abdurrahman I Islim; Christopher P Millward; Rory J Piper; Daniel M Fountain; Shaveta Mehta; Ruwanthi Kolamunnage-Dona; Usama Ali; Shelli Diane Koszdin; Theo Georgious; Samantha J Mills; Andrew R Brodbelt; Ryan K Mathew; Thomas Santarius; Michael D Jenkinson Journal: BMJ Open Date: 2022-01-18 Impact factor: 2.692